Molecular Templates Inc (MTEM) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access MTEM Annual Balance Sheets →
Balance sheet data covering Molecular Templates Inc–Jun 30 2023 offers a view into how Jun 30 2024's financial position has changed alongside business activity.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2024)
(Mar 31 2024) (Dec 31 2023) (Sep 30 2023) (Jun 30 2023)
Assets
Cash & cash equivalent9.66
Cash & Short-term Investments9.00
Grants Receivable, Current0.80
Other Current Assets0.78
Prepaid Expense, Current AS0.79
Total Current Assets12.02
Equipment/Property/Plant Net5.24
Other Assets, Noncurrent9.00
Operating Lease Right Of Use Asset8.12
Total Assets26.70
Liabilities
Accounts Payable, Current AC2.77
Accrued Liabilities, Current AC2.27
Other Liabilities, Current2.64
Deferred Revenue, Current DE0.00
Total Current Liabilities7.68
Total Long-term Debt0.00
Deferred Revenue, Noncurrent DE0.00
Other liabilities, Noncurrent11.91
Operating Lease Liability Noncurrent8.39
Total Liabilities19.59
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock467.52
Retained Earnings / Accumulated Deficit-460.42
Other Equity0.00
Common Stockholder's Equity7.11
Total Stockholder's Equity7.11
Liabilities & Stockholder's Equity26.70
4 historic quarters locked

Sign in to unlock the full Molecular Templates Inc balance sheet history.

About Molecular Templates Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001558370-24-012257

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.